Department of Dermatology, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
Acta Derm Venereol. 2024 Oct 10;104:adv40447. doi: 10.2340/actadv.v104.40447.
Telangiectasia macularis multiplex acquisita is an acquired cutaneous telangiectasis of unknown aetiology, and it lacks both effective and cost-efficient treatment. This study aims to identify a novel potential associated factor of the disease and explore feasible therapeutic interventions. In this retrospective case series study, 46 Chinese patients diagnosed with telangiectasia macularis multiplex acquisita between 1 January 2007 and 18 May 2023 were included. The median age of onset was 43 years (23 to 60 years), and the male to female ratio was 10.5:1. Besides previously reported associations including chronic liver disorders, alcohol consumption, and smoking, a potential association was found between use of calcium channel blockers and development of telangiectasia macularis multiplex acquisita. Twenty-two of 27 hypertensive patients took calcium channel blockers, with 17 followed up. Ten out of 17 displayed a range of improvements following the cessation of calcium channel blockers; 1 patient reported no lesion change post-discontinuation of calcium channel blockers; 1 patient continued their medication but showed partial improvement after 2 pulsed dye laser treatments; 1 patient observed lesion colour lightening without altering hypertensive medication or other specific treatments; and another 4 kept their previous hypertensive regimen due to blood pressure stability concerns, with no change in their lesions. The study proposes that cessation of calcium channel blockers can be a novel therapeutic approach for affected individuals.
获得性多发性毛细血管扩张症是一种病因不明的获得性皮肤毛细血管扩张症，目前缺乏有效且经济高效的治疗方法。本研究旨在寻找一种新的潜在相关因素，并探索可行的治疗干预措施。在这项回顾性病例系列研究中，纳入了 2007 年 1 月 1 日至 2023 年 5 月 18 日期间被诊断为获得性多发性毛细血管扩张症的 46 例中国患者。发病中位年龄为 43 岁（23 岁至 60 岁），男女比例为 10.5:1。除了先前报道的与慢性肝脏疾病、酒精摄入和吸烟有关的关联外，还发现钙通道阻滞剂的使用与获得性多发性毛细血管扩张症的发生之间存在潜在关联。27 例高血压患者中有 22 例服用钙通道阻滞剂，其中 17 例进行了随访。17 例中有 10 例在停用钙通道阻滞剂后表现出不同程度的改善；1 例患者在停用钙通道阻滞剂后报告病变无变化；1 例患者在接受 2 次脉冲染料激光治疗后显示部分改善；1 例患者观察到病变颜色变浅，而未改变高血压药物或其他特定治疗；另外 4 例由于担心血压稳定而继续使用以前的高血压治疗方案，病变无变化。该研究提出，停用钙通道阻滞剂可能是一种新的治疗方法。
